3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
27
Docetaxel
20
Cyclophosphamide
18
Surveys and Questionnaires
15
Therapeutics
14
Radiotherapy
13
Paclitaxel
12
Psychiatric Rehabilitation
11
Early Intervention, Educational
11
Carboplatin
11
Standard of Care
10
olaparib
9
Zoledronic Acid
9
Specimen Handling
9
Radiosurgery
9
Magnetic Resonance Spectroscopy
9
Interviews as Topic
9
Gemcitabine
9
Trastuzumab
8
Methods
8
Fulvestrant
8
palbociclib
7
fludarabine
7
durvalumab
7
Taxes
7
Nivolumab
7
Fluorodeoxyglucose F18
7
Flow Cytometry
7
Educational Status
7
Blood Specimen Collection
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Tinzaparin
×
Genitourinary
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled